Top Section/Ad
Top Section/Ad
Most recent
Investors saw plenty of juice in first public AT1 from Chile as regulatory framework draws praise
Mexican lender falls short of bond size target as late 2023 momentum fades
◆ US RMBS sales in Europe: immigration or vacation? ◆ UBS AT1 makes nonsense of claims of investor fears ◆ The EU's last hurrah in the SSA market
◆ IG investors comfort eat sweet spreads ◆ What can FIG issuers do now? ◆ US HEI securitizations: mainstream or flash in pan?
More articles/Ad
More articles/Ad
More articles
-
Banca Carige has shaken up its management team and is preparing to return to the European Central Bank with a new plan for keeping its capital ratios in check. But the troubled Italian lender is going to have its work cut out in accessing the debt or equity markets before the end of the year, with a whole host of its peers waiting to do the same, write Tyler Davies and Sam Kerr. -
Prudential plc came to the market on Wednesday for a strategic deal to boost the capital position of a prospective entity it plans to cut loose, M&G Prudential. Those on the buy-side saw the notes as cheap, notwithstanding any extra cost for a clause allowing for issuer substitution.
-
Société Générale has come to the market for the fifth time this month, looking to raise additional tier one capital in dollars. Initial price thoughts were seen as closer to fair value than for other recent AT1s.
-
Nordea Bank's move into Finland next week will reveal the huge problems facing an incomplete Banking Union.
-
Asian equities showed mixed responses to the increase in the federal funds rate announced by the Federal Open Market Committee (FOMC) on Wednesday night, while bonds in the region held up reasonably well. But there are worries that the pace of rate hikes until the end of 2019 might be too aggressive.
-
Hanwha General Insurance’s failed attempt at a tier two dollar bond last week shows that not all South Korean credits can win over investors, as the buy-side looks at the country’s insurance borrowers with a lack of enthusiasm and a healthy dose of scepticism. With more Korean insurers set to hit the market, it’s time they reassess their approach to fundraisings.
